Vault, viral, and virus-like nanoparticles for targeted cancer therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F46747885%3A24620%2F23%3A00012260" target="_blank" >RIV/46747885:24620/23:00012260 - isvavai.cz</a>

Výsledek na webu

<a href="https://pubs.rsc.org/en/content/articlelanding/2023/ma/d3ma00171g" target="_blank" >https://pubs.rsc.org/en/content/articlelanding/2023/ma/d3ma00171g</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1039/d3ma00171g" target="_blank" >10.1039/d3ma00171g</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Vault, viral, and virus-like nanoparticles for targeted cancer therapy

Popis výsledku v původním jazyce

Despite different strategies routinely applied for cancer therapy such as chemotherapy, surgery, and radiotherapy or a combination of them, they are still beleaguered by poor long-term survival rates, possible toxic/side effects, low therapeutic efficiency, and poor targeting attributes. Nanotechnology can help to develop advanced and selective tactics and nanosystems with fewer side effects, enhanced biosafety, improved targeting properties, and high therapeutic efficiency; assorted advanced nanosystems have been introduced to overcome drug resistance, showing improved rate of survival. In this context, vault, viral, and virus-like nanoparticles (NPs) with unique properties and structures can be deployed for smart targeted cancer therapy. Vaults are interesting examples of naturally occurring NPs mimicking diverse features of viral delivery tools without the significant risk of an immunological response, as they are an endogenous cellular component. The modifications of their primary sequences can enhance their capability for specific targeting properties and efficient encapsulation of bioactive molecules. In addition, virus-like particles have been studied for targeted anticancer drug delivery as well as cancer immunotherapy/vaccination and antitumor immunity. Thus, viral and virus-like NPs have excellent potential for targeted cancer therapy, with promise for multivalent antigen presentation and drug delivery. However, comprehensive clinical trials/studies are still required for ensuring their biosafety and efficacy. This highlight deliberates the current state-of-the-knowledge on the topic focusing on recent advances pertaining to the applications of vault, viral, and virus-like NPs for targeted cancer therapy.

Název v anglickém jazyce

Vault, viral, and virus-like nanoparticles for targeted cancer therapy

Popis výsledku anglicky

Despite different strategies routinely applied for cancer therapy such as chemotherapy, surgery, and radiotherapy or a combination of them, they are still beleaguered by poor long-term survival rates, possible toxic/side effects, low therapeutic efficiency, and poor targeting attributes. Nanotechnology can help to develop advanced and selective tactics and nanosystems with fewer side effects, enhanced biosafety, improved targeting properties, and high therapeutic efficiency; assorted advanced nanosystems have been introduced to overcome drug resistance, showing improved rate of survival. In this context, vault, viral, and virus-like nanoparticles (NPs) with unique properties and structures can be deployed for smart targeted cancer therapy. Vaults are interesting examples of naturally occurring NPs mimicking diverse features of viral delivery tools without the significant risk of an immunological response, as they are an endogenous cellular component. The modifications of their primary sequences can enhance their capability for specific targeting properties and efficient encapsulation of bioactive molecules. In addition, virus-like particles have been studied for targeted anticancer drug delivery as well as cancer immunotherapy/vaccination and antitumor immunity. Thus, viral and virus-like NPs have excellent potential for targeted cancer therapy, with promise for multivalent antigen presentation and drug delivery. However, comprehensive clinical trials/studies are still required for ensuring their biosafety and efficacy. This highlight deliberates the current state-of-the-knowledge on the topic focusing on recent advances pertaining to the applications of vault, viral, and virus-like NPs for targeted cancer therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20500 - Materials engineering

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Materials Advances

ISSN

2633-5409

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

14

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

2909 - 2917

Kód UT WoS článku

001016277000001

EID výsledku v databázi Scopus

2-s2.0-85164183311